These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1171 related articles for article (PubMed ID: 29064348)

  • 1. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
    Aris P; Boroumand MA; Rahbar M; Douraghi M
    Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
    Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
    Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
    Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
    J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-spectrum β-lactamase-producing Enterobacteriaceae: in vitro susceptibility to fosfomycin, nitrofurantoin and tigecycline.
    Al-Zarouni M; Senok A; Al-Zarooni N; Al-Nassay F; Panigrahi D
    Med Princ Pract; 2012; 21(6):543-7. PubMed ID: 22722224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Activity of fosfomycin against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae].
    de Cueto M; Hernández JR; López-Cerero L; Morillo C; Pascual A
    Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):613-6. PubMed ID: 17194386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary Tract Infections in Kidney Transplant Patients Due to Escherichia coli and Klebsiella pneumoniae-Producing Extended-Spectrum β-Lactamases: Risk Factors and Molecular Epidemiology.
    Espinar MJ; Miranda IM; Costa-de-Oliveira S; Rocha R; Rodrigues AG; Pina-Vaz C
    PLoS One; 2015; 10(8):e0134737. PubMed ID: 26237422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
    Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
    Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral treatment options for patients with urinary tract infections caused by extended spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
    Raja NS
    J Infect Public Health; 2019; 12(6):843-846. PubMed ID: 31176606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of fosfomycin and other antimicrobials against uropathogenic Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon.
    Araj GF; Jaber FA
    J Med Liban; 2012; 60(3):142-7. PubMed ID: 23198454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefoxitin-based antibiotic therapy for extended-spectrum β-lactamase-producing Enterobacteriaceae prostatitis: a prospective pilot study.
    Demonchy E; Courjon J; Ughetto E; Durand M; Risso K; Garraffo R; Roger PM
    Int J Antimicrob Agents; 2018 Jun; 51(6):836-841. PubMed ID: 29378342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years.
    Toner L; Papa N; Aliyu SH; Dev H; Lawrentschuk N; Al-Hayek S
    World J Urol; 2016 Jul; 34(7):1031-7. PubMed ID: 26511749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The antimicrobial activity of mecillinam, nitrofurantoin, temocillin and fosfomycin and comparative analysis of resistance patterns in a nationwide collection of ESBL-producing Escherichia coli in Norway 2010-2011.
    Zykov IN; Sundsfjord A; Småbrekke L; Samuelsen Ø
    Infect Dis (Lond); 2016 Feb; 48(2):99-107. PubMed ID: 26414659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.
    Garau J
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():198-202. PubMed ID: 18154548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-Spectrum beta (β)-Lactamases and Antibiogram in Enterobacteriaceae from Clinical and Drinking Water Sources from Bahir Dar City, Ethiopia.
    Abera B; Kibret M; Mulu W
    PLoS One; 2016; 11(11):e0166519. PubMed ID: 27846254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of Enterobacteriaceae isolates obtained from a tertiary care hospital in Mexico, which produces extended-spectrum β-lactamase.
    Morfín-Otero R; Mendoza-Olazarán S; Silva-Sánchez J; Rodríguez-Noriega E; Laca-Díaz J; Tinoco-Carrillo P; Petersen L; López P; Reyna-Flores F; Alcantar-Curiel D; Garza-Ramos U; Garza-González E
    Microb Drug Resist; 2013 Oct; 19(5):378-83. PubMed ID: 23725513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of fosfomycin tromethamine against extended spectrum beta-lactamase producing urinary tract bacteria.
    Khan IU; Mirza IA; Ikram A; Ali S; Hussain A; Ghafoor T
    J Coll Physicians Surg Pak; 2014 Dec; 24(12):914-7. PubMed ID: 25523727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging Perils of Extended Spectrum
    Parajuli NP; Maharjan P; Joshi G; Khanal PR
    Biomed Res Int; 2016; 2016():1782835. PubMed ID: 28119921
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevalence of extended-spectrum β-lactamase (ESBL) and molecular detection of
    Dirar MH; Bilal NE; Ibrahim ME; Hamid ME
    Pan Afr Med J; 2020; 37():213. PubMed ID: 33520052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended-spectrum beta-lactamase-producing
    Romyasamit C; Sornsenee P; Kawila S; Saengsuwan P
    Microbiol Spectr; 2024 Jul; 12(7):e0021324. PubMed ID: 38809095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial susceptibility and emerging resistance determinants (blaCTX-M, rmtB, fosA3) in clinical isolates from urinary tract infections in the Bolivian Chaco.
    Bartoloni A; Sennati S; Di Maggio T; Mantella A; Riccobono E; Strohmeyer M; Revollo C; Villagran AL; Pallecchi L; Rossolini GM
    Int J Infect Dis; 2016 Feb; 43():1-6. PubMed ID: 26686940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.